Open Label Study to Evaluate the Safety, Tolerability and Biodegradation Period of PA5346 Latanoprost Free Acid (FA) Sustained Release (SR) Ocular Implant When Administered to Patients With Open Angle Glaucoma or Ocular Hypertension
Latest Information Update: 17 Apr 2024
Price :
$35 *
At a glance
- Drugs Latanoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors PolyActiva
- 17 Apr 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 11 Apr 2024 Status changed from recruiting to completed.
- 10 Mar 2022 Status changed from not yet recruiting to recruiting.